Incorporating: Eloquence Languages and Translations

It's in the air!    

22 Million people are known to have asthma in the US alone. It is the leading cause of hospital emergency visits and school absenteeism. Most families including yours have at least one member who is, was or will be affected by a respiratory disease or disorder.
 
This month Judy was back working in the context of respiratory diseases. Two years ago she ran a series of workshops training lung specialists and GPs to use Transactional Analysis to help guide their patients through the stages of change and transition in the context of using a new inhaler to treat asthma. The aim was to increase compliance and enhance device and inhalation technique
 
This time Judy was working as an interpreter at TEVA RespiDays in Paris, a two day Scientific Respiratory Symposium which brought together experts from Europe and the US to present and discuss the latest research and medical advancements in the field.

 

 

The conference which was co-chaired by Professors Bousquet and Roche was of an exceptionally high standard. Over two days delegates were able to attend expert presentations and workshops in both French and English. As Professor Bousquet underlined Chronic Respiratory Disease is very firmly on the political and healthcare agenda worldwide and as Professor Andrew Briggs pointed out, this has become an economic issue when you consider that the financial cost of COPD to the health service is an estimated £ Delegates attend the RespiDays presentations486M to £850 in the UK alone and that indirect (productivity) costs could double this!

Professor Roche in his presentation on Real Life Device Trials brought up the issue of poor inhalation technique and the frightening figure that out of 16,580 real-life asthmatics, asthma control was unacceptable for 72% of patients. Although there are multiple contributing factors such as inadequate assessment of control and maintenance therapy, Rhinitis, GER, environmental exposures, smoking and being overweight, the foremost contributing factors were device and inhalation technique and poor compliance. A range of topics was covered over the two days and Mark Milton-Edwards (Global Marketing Director, Respiratory) of TEVA Pharmaceuticals Ltd commented that ‘there is much to be gained for society and individuals around the globe if we successfully develop both new but also more cost-effective products.’Judy chats to fellow interpreter Audrey Kyler-Goujon

Mark Milton-Edwards

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 15 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Western Europe.
 
 
The BOZ team who were responsible for organising the logistics at TEVA RespiDays            Judy chats to Dr Lucie Brémaud Client Services Director  at BOZ